Consequently, the Kidney Disease: Improving Global Outcomes (KDIGO) 2024 Clinical Practice Guideline recommends avoiding any combination of ACEi, ARB, and direct renin inhibitors in patients with CKD, regardless of diabetes status [64]. This evidence concerns the gene REN and diabetes mellitus.